Teva Pharmaceutical Statistics
Total Valuation
Teva Pharmaceutical has a market cap or net worth of $33.10 billion. The enterprise value is $46.36 billion.
Important Dates
The next confirmed earnings date is Wednesday, April 29, 2026, before market open.
| Earnings Date | Apr 29, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Teva Pharmaceutical has 1.15 billion shares outstanding. The number of shares has increased by 2.83% in one year.
| Current Share Class | n/a |
| Shares Outstanding | 1.15B |
| Shares Change (YoY) | +2.83% |
| Shares Change (QoQ) | +0.77% |
| Owned by Insiders (%) | 0.46% |
| Owned by Institutions (%) | 69.88% |
| Float | 1.08B |
Valuation Ratios
The trailing PE ratio is 23.78 and the forward PE ratio is 10.72. Teva Pharmaceutical's PEG ratio is 4.18.
| PE Ratio | 23.78 |
| Forward PE | 10.72 |
| PS Ratio | 1.89 |
| Forward PS | 1.92 |
| PB Ratio | 4.18 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | 28.47 |
| P/OCF Ratio | 19.82 |
| PEG Ratio | 4.18 |
Financial Ratio HistoryEnterprise Valuation
The stock's EV/EBITDA ratio is 9.36, with an EV/FCF ratio of 40.39.
| EV / Earnings | 32.88 |
| EV / Sales | 2.69 |
| EV / EBITDA | 9.36 |
| EV / EBIT | 11.73 |
| EV / FCF | 40.39 |
Financial Position
The company has a current ratio of 1.04, with a Debt / Equity ratio of 2.18.
| Current Ratio | 1.04 |
| Quick Ratio | 0.54 |
| Debt / Equity | 2.18 |
| Debt / EBITDA | 3.39 |
| Debt / FCF | 15.01 |
| Interest Coverage | 4.31 |
Financial Efficiency
Return on equity (ROE) is 20.79% and return on invested capital (ROIC) is 18.08%.
| Return on Equity (ROE) | 20.79% |
| Return on Assets (ROA) | 6.17% |
| Return on Invested Capital (ROIC) | 18.08% |
| Return on Capital Employed (ROCE) | 14.48% |
| Weighted Average Cost of Capital (WACC) | 6.81% |
| Revenue Per Employee | $508,336 |
| Profits Per Employee | $41,532 |
| Employee Count | 33,950 |
| Asset Turnover | 0.43 |
| Inventory Turnover | 2.69 |
Taxes
| Income Tax | -180.00M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +76.77% in the last 52 weeks. The beta is 0.72, so Teva Pharmaceutical's price volatility has been lower than the market average.
| Beta (5Y) | 0.72 |
| 52-Week Price Change | +76.77% |
| 50-Day Moving Average | 32.49 |
| 200-Day Moving Average | 23.96 |
| Relative Strength Index (RSI) | 30.38 |
| Average Volume (20 Days) | 7,492,053 |
Short Selling Information
The latest short interest is 32.53 million, so 2.81% of the outstanding shares have been sold short.
| Short Interest | 32.53M |
| Short Previous Month | 37.95M |
| Short % of Shares Out | 2.81% |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 3.37 |
Income Statement
In the last 12 months, Teva Pharmaceutical had revenue of $17.26 billion and earned $1.41 billion in profits. Earnings per share was $1.21.
| Revenue | 17.26B |
| Gross Profit | 8.94B |
| Operating Income | 3.95B |
| Pretax Income | 1.24B |
| Net Income | 1.41B |
| EBITDA | 4.95B |
| EBIT | 3.95B |
| Earnings Per Share (EPS) | $1.21 |
Full Income StatementBalance Sheet
The company has $3.56 billion in cash and $17.23 billion in debt, with a net cash position of -$13.67 billion or -$11.89 per share.
| Cash & Cash Equivalents | 3.56B |
| Total Debt | 17.23B |
| Net Cash | -13.67B |
| Net Cash Per Share | -$11.89 |
| Equity (Book Value) | 7.91B |
| Book Value Per Share | 6.88 |
| Working Capital | 490.00M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was $1.65 billion and capital expenditures -$501.00 million, giving a free cash flow of $1.15 billion.
| Operating Cash Flow | 1.65B |
| Capital Expenditures | -501.00M |
| Depreciation & Amortization | 1.00B |
| Net Borrowing | -1.81B |
| Free Cash Flow | 1.15B |
| FCF Per Share | $1.00 |
Full Cash Flow StatementMargins
Gross margin is 51.79%, with operating and profit margins of 22.90% and 8.17%.
| Gross Margin | 51.79% |
| Operating Margin | 22.90% |
| Pretax Margin | 7.17% |
| Profit Margin | 8.17% |
| EBITDA Margin | 28.71% |
| EBIT Margin | 22.90% |
| FCF Margin | 6.65% |
Dividends & Yields
Teva Pharmaceutical does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -2.83% |
| Shareholder Yield | -2.83% |
| Earnings Yield | 4.31% |
| FCF Yield | 3.51% |
Dividend DetailsAnalyst Forecast
The average price target for Teva Pharmaceutical is $37.38, which is 29.84% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $37.38 |
| Price Target Difference | 29.84% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 8 |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | |
| Graham Upside | |
Stock Splits
The last stock split was on July 1, 2004. It was a forward split with a ratio of 2:1.
| Last Split Date | Jul 1, 2004 |
| Split Type | Forward |
| Split Ratio | 2:1 |
Scores
Teva Pharmaceutical has an Altman Z-Score of 0.68 and a Piotroski F-Score of 8. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 0.68 |
| Piotroski F-Score | 8 |
